- WKN: 621993
- ISIN: DE0006219934
- Land: Deutschland
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
29. November 16:16 Skechers weiterhin im Dolce-Vita-Look
29. November 16:24 Gazprom: 100 Prozent seit Empfehlung - und nun mit neuem Rekordgewinn
29. November 17:02 Tesla, BYD, Valneva: Große Performance zum kleinen Preis – nur noch ...
29. November 17:10 DAX: Das war mau
29. November 17:15 Alibaba dringt ins Tencent-Universum ein
Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.
29. November 2021